Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
0.7201
Oct 22 • 4:00 PM ET Dollar change-0.0439 Percentage change(-5.75%)
Aftermarket Close
0.7060
Aftermarket • 7:54 PM ET Dollar change-0.0141 Percentage change(-1.96%)
Index
-
Market Cap
2.19M
Enterprise Value
-8.72M
Income
-5.32M
Sales
0.03M
Book/sh
5.22
Cash/sh
3.80
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
7
IPO
Sep 01, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
73.00
P/B
0.14
P/C
0.19
P/FCF
-
EV/EBITDA
-
EV/Sales
-290.67
Quick Ratio
5.07
Current Ratio
5.07
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-5.28
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
80.39% 55.23%
Sales past 3/5Y
- -
EPS Y/Y TTM
99.47%
Sales Y/Y TTM
-
EPS Q/Q
-3.64%
Sales Q/Q
-
Insider Own
0.00%
Insider Trans
-
Inst Own
13.27%
Inst Trans
0.19%
ROA
-35.16%
ROE
-43.75%
ROIC
-33.51%
Gross Margin
-3716.13%
Oper. Margin
-16629.03%
Profit Margin
-17158.06%
SMA20
-15.97%
SMA50
-22.42%
SMA200
-62.66%
Trades
Shs Outstand
0.03M
Shs Float
-
52W High
7.95 -90.94%
52W Low
0.69 4.18%
Volatility
8.56% 5.60%
ATR (14)
0.07
RSI (14)
32.01
Beta
1.13
Rel Volume
0.13
Avg Volume
281.20K
Volume
37,617
Perf Week
-14.88%
Perf Month
-27.99%
Perf Quarter
-36.56%
Perf Half Y
-70.12%
Perf YTD
-77.56%
Perf Year
-88.10%
Perf 3Y
-99.75%
Perf 5Y
-99.98%
Perf 10Y
-
Prev Close
0.76
Price
0.72
Change %
-5.75%
PRF Technologies Ltd. is a pharmaceutical company, which focuses on reformulation of established therapeutics. It offers PRF-110, an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. The company was founded by Lihu Avitov and Dan Teleman in 2007 and is headquartered in Herzliya, Israel.
Executive ChairmanDr. Ehud Geller Ph.D.
Chief Financial OfficerMr. Eyal Broder
Ph.D.Dr. Sigal Aviel eMBA
Interim CEO & DirectorMr. Efraim Cohen-Arazi
Vice President of Pharmaceutical OperationsMs. Rita Keynan M.Sc.